Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (XYRIS)

Bayer

Status: Withdrawn

Conditions: Prophylaxis, Thromboembolism, Venous; Total Hip Replacement; Total Knee Replacement

Treatments: Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT01523418

15871

XA1111IN (Other Identifier)

Details and patient eligibility

About

The primary objective of this study is to evaluate the safety of Xarelto in the prophylaxis of VTE in Indian patients undergoing elective TKR/THR

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients of either sex, undergoing elective THR/TKR, in whom, Rivaroxaban is given for thromboprophylaxis
• Patients willing to give a written informed consent

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information
• Patients on UFH / LMWH therapy, fondaparinux and vitamin K antagonists are not eligible.
• Patients with history of hypersensitivity to active ingredients or excipient :cellulose microcrystalline, croscarmellose sodium, lactose monohydrate, magnesium stearate, sodium lauryl sulfate

Trial design

0 participants in 1 patient group

Group 1

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)